<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="60137"><DrugName>viloxazine hydrochloride  (once-daily, depression), Supernus</DrugName><DrugNamesKey><Name id="42748520">viloxazine</Name></DrugNamesKey><DrugSynonyms><Name><Value>viloxazine</Value><Types><Type>INN</Type></Types></Name><Name><Value>viloxazine (once-daily, depression), Supernus</Value></Name><Name><Value>viloxazine hydrochloride  (once-daily, depression), Supernus</Value></Name><Name><Value>SPN-809</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>46817-91-8</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>35604-67-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24657">Supernus Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="24657">Supernus Pharmaceuticals Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="60137" type="Drug"><TargetEntity id="477288" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="24657" type="Company"><TargetEntity id="4297350707" type="organizationId">Supernus Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="285" type="Action"><TargetEntity id="63" type="Mechanism">Norepinephrine Reuptake Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><IndicationsPrimary><Indication id="93">Depression</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="60">Central nervous system disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="285">Norepinephrine uptake inhibitor</Action><Action id="2941">Antidepressant</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N</Code><Name>CENTRAL NERVOUS SYSTEM</Name></Ephmra><Ephmra><Code>N6A5</Code><Name>SRNI antidepressants</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-18T12:38:22.000Z</LastModificationDate><ChangeDateLast>2018-03-27T00:00:00.000Z</ChangeDateLast><AddedDate>2008-05-08T17:07:08.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24657" linkType="Company"&gt;Supernus&lt;/ulink&gt;, using intellectual property and market analysis acquired from &lt;ulink linkID="1132907" linkType="Company"&gt;Rune Healthcare&lt;/ulink&gt;,  is developing SPN-809, a once-daily formulation of the  norepinephrine reuptake inhibitor viloxazine,  for the potential treatment of depression. The undisclosed compound had previously been launched in the EU for depression   [&lt;ulink linkID="903900" linkType="Reference"&gt;903900&lt;/ulink&gt;], [&lt;ulink linkID="1235543" linkType="Reference"&gt;1235543&lt;/ulink&gt;]. In September 2013, the drug was listed as being in phase II development [&lt;ulink linkID="1479311" linkType="Reference"&gt;1479311&lt;/ulink&gt;]. In March 2016 and March 2017, Supernus described the drug as "ready for phase II" [&lt;ulink linkID="1742118" linkType="Reference"&gt;1742118&lt;/ulink&gt;], [&lt;ulink linkID="1904194" linkType="Reference"&gt;1904194&lt;/ulink&gt;]. In February 2018, the program was listed as in phase I on the company's pipeline [&lt;ulink linkID="2004820" linkType="Reference"&gt;2004820&lt;/ulink&gt;].  In November 2011, the company was seeking to outlicense its programs [&lt;ulink linkID="1235543" linkType="Reference"&gt;1235543&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Supernus was previously   investigating the drug for CNS indication [&lt;ulink linkID="903900" linkType="Reference"&gt;903900&lt;/ulink&gt;]; however, in November 2011,  this indication was no longer listed as being under investigation [&lt;ulink linkID="1235543" linkType="Reference"&gt;1235543&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By May 2008, phase I trials for depression  had been scheduled to start  later that year [&lt;ulink linkID="903900" linkType="Reference"&gt;903900&lt;/ulink&gt;]. By December 2008 an IND had been  filed [&lt;ulink linkID="990925" linkType="Reference"&gt;990925&lt;/ulink&gt;]. In June 2011, the company planned to initiate phase IIb study [&lt;ulink linkID="1284704" linkType="Reference"&gt;1284704&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24657">Supernus Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2018-02-13T00:00:00.000Z</StatusDate><Source id="2004820" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24657">Supernus Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate>2011-11-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24657">Supernus Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate>2008-05-08T00:00:00.000Z</StatusDate><Source id="903900" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24657">Supernus Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2008-05-08T00:00:00.000Z</StatusDate><Source id="903900" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24657">Supernus Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2013-09-19T00:00:00.000Z</StatusDate><Source id="1479311" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1132907">Rune Healthcare</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24657">Supernus Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCOc1ccccc1OCC2CNCCO2.Cl</Smiles><Smiles>CCOc1ccccc1OCC2CNCCO2</Smiles></StructureSmiles><Deals><Deal id="178171" title=" RH Market Analysis and supportive intelligence data related to SPN-809 (norepinepherine reuptake inhibitor)"/></Deals><PatentFamilies><PatentFamily id="2343958" number="WO-2010090991" title="Formulations of desvenlafaxine"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Supernus Pharmaceuticals Inc" id="24657"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>